PROGRAMME



Luis Mariano Ferreira Page 1/2

Thursday, January 28, 2021 **MAIN ARENA 1** 16:15 - 18:00 Current concepts, innovations, and open questions in EVAR of complex infrarenal aortoiliac aneurysms MODERATOR: Giovanni Torsello Frank Veith PANEL: Armando Lobato Fric Verhoeven Konstantinos Donas 16:15 - 16:40 Live case transmission from Paris Hôpital Marie Lannelongue Paris - Live case center 16:40 - 16:45 Best practices and technical learning on the on-label treatment of challenging necks: The EXCeL registry Marc van Sambeek Contemporary options for treating juxtarenal aneurysm when infrarenal sealing is not enough 16:45 - 16:50 Konstantinos Donas EndoAnchors can facilitate and maintain successful standard EVAR for AAAs with challenging 16:50 - 16:55 proximal necks Luis Mariano Ferreira 16:55 - 17:00 FEVAR technique – a case presentation Eric Ducasse 4xFEVAR: is it always needed to stent the celiac artery? 17:00 - 17:05 Eric Verhoeven 17:05 - 17:10 Data on the 3 year clinical results of BeGraft in FEVAR Stéphan Haulon Insight in the German FEVAR approval study to get bridging stents approved for the indication 17:10 - 17:15 Eric Verhoeven WeFlow-JAAA™: a new uncustomized device for juxtarenal AAA 17:15 - 17:20 Wei Guo

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME



Luis Mariano Ferreira Page 2/2

Thursday, January 28, 2021	
17:20 – 17:25	Type II endoleak and aortic aneurysm sac shrinkage after pre-emptive embolization of aneurysm sac side branches Daniela Branzan
17:25 – 17:40	Live case transmission from Leipzig Universitätsklinikum Leipzig, Abt. Angiologie - Live case center
17:40 – 17:45	How stent graft design influences overall AAA sac dynamics and overall therapy success
17:45 – 17:50	EVAR long term perspectives: facts and figures from the GREAT registry experience at 5 years Chandler Long
17:50 – 17:55	How and why do the Endurant endograft results for EVAR in France differ from the global results: what are the implications Jean-Pierre Becquemin
17:55 – 18:00	How sac regression at 1 year affects all-cause mortality through 5 year: key insights from the ENGAGE registry Michel Reijnen